In-house IP roundup: blue-v-blue biologic litigation rises; UPC apathy after new complaint listing; businesses shed patents for cost savings

splash

Zentiva, Insud Pharma and an originator drug company explain how large molecule market dynamics have shifted the litigation format created by small molecule products, turning other generics and innovators into litigation targets. (Read more … ) 

In-house counsel explain what they’ve done so far to prepare for the Unified Patent Court, but say they’re unlikely to increase preparations, despite the complaint holding up the system’s creation being moved to this year’s agenda. (Read more … )

Patent departments say financial constraints have compelled more businesses to abandon or sell off less valuable registrations – but they add that they are careful not to get rid of the wrong ones. (Read more … )

Sign up to receive more content like this in Patent Strategy’s weekly newsletter.